Authors
Latest:
EEG TalkEEG Talk is a series dedicated to teaching electroencephalogram (EEG) reading skills in neurology in a way that is both digestible and fun. New episodes featuring special guests in the field are posted regularly on Mondays.
Latest:
The Future of Innovative Neurorestoration Approaches: Joe Kardine, MS, OTR, CBISThe clinical program manager at the Jefferson Center for Neurorestoration provided commentary on the state of neurorestoration and constant transformation of the space. [WATCH TIME: 3 minutes]
Latest:
Strategies for Managing Changes in Cognitive Function in Multiple Sclerosis: Meghan Beier, PhD, MAIn recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]
Latest:
The State of Biomarkers in Multiple SclerosisAs the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Latest:
Need for Research on Social Determinants of Health for Stroke Outcomes: Ralph Sacco, MD, MS, FAAN, FAHAThe chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.
Latest:
The Impact of Dystrophin Levels on Duchenne Muscular Dystrophy ProgressionA panelist discusses how even very small amounts of dystrophin (as low as 1%) may slow disease progression in skeletal muscles, although the impact on cardiac and respiratory function remains less clear.
Latest:
Technological Advances Leading the Future of Parkinson Care: Cheryl Kyinn, PA-CA physician assistant specializing in Parkinson disease talked about how emerging technologies and proactive care models could transform the treatment landscape for Parkinson disease. [WATCH TIME: 4 minutes]
Latest:
Episode 5: Emerging Women-Related Research and Closing ThoughtsThe group of women neurologists provided commentary on the critical areas of women-focused research in neurology, from clinical trial participation to addressing workforce challenges.
Latest:
CMSC Live: 2025 Annual Meeting Day 3Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.
Latest:
Changing the Perception and Conversation Around Disability: Sarah Todd HammerHammer, a patient advocate living with acute flaccid myelitis, discussed the language around neurologic disability, and how the conversations should shift going forward. [WATCH TIME: 4 minutes]
Latest:
Potential of Device-Assisted Therapy for Advanced-Stage Parkinson Disease: David Devos, MD, PhDThe neuropharmacologist at the University of Lille, in France, provided commentary on promising results from the phase 1/2 DIVE-I trial assessing the safety and efficacy of a device-assisted therapy in Parkinson disease. [WATCH TIME: 6 minutes]
Latest:
Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhDThe full professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]
Latest:
Parkinson Disease Subtyping: Are We There Yet?Heterogeneity suggests that identifying different types of Parkinson disease could improve patient management, the understanding of underlying disease mechanisms, and the development of target-specific therapies.
Latest:
AUPN Leadership Minute Episode 37: International Physicians in NeurologyEpisode 37 of the AUPN Leadership Minute features David G. Standaert, MD, PhD, of the University of Alabama at Birmingham; and Erica A. Schuyler, MD, of the University of Connecticut. [WATCH TIME: 5 minutes]
Latest:
Diagnostic Criteria, Phenotypes and Epidemiology of Autoimmune Encephalitis: Divyanshu Dubey, MBBSThe assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]
Latest:
Individualizing Disease-Modifying Therapy Selection in Newly Diagnosed MS: Gabrielle Macaron, MDThe assistant professor in the Department of Neuroscience at Université de Montréal discussed key clinical factors influencing DMT selection in patients newly diagnosed with multiple sclerosis. [WATCH TIME: 5 minutes]
Latest:
Joaquim Ferreira, MD, PhD: The Magnitude of Effect for Opicapone in Parkinson DiseaseThe head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.
Latest:
Optimizing Care for SCN8A Epilepsy and Related Disorders: Gabi Conecker; JayEtta HeckerRepresentatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]
Latest:
Evolving Understanding and Treatment of Smoldering Multiple Sclerosis: Antonio Scalfari, MD, PhDThe consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]
Latest:
A National Registry Analysis on Minimally Invasive Surgery for Intracerebral Hemorrhage: Santosh Murthy, MD, MPHThe associate professor of neurology at Weill Cornell Medicine talked about a recent study that revealed that minimally invasive surgery significantly reduced the risk of mortality in patients with nontraumatic intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Latest:
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhDThe senior vice president of research at Gain Therapeutics talked about preclinical findings from a study assessing GT-02287, an agent in development for the treatment of GBA1 Parkinson disease, and future plans for clinical trials. [WATCH TIME: 7 minutes]
Latest:
Stroke Intervention: A New Application of Interventional NeuroradiologyNew training pathways are needed to close the gap between capable-physician supply and the growing demand for thrombectomy.
Latest:
Swallow This: Treating Dysphagia with Speech PathologyStephanie Richardson, MS, CCC-SLP, an outpatient lead speech-language pathologist at Brooks Rehabilitation, discussed the unique aspects of speech therapy and the pivotal role it plays in helping patients with swallowing and other related functions.
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
Latest:
The Outlook for Apitegromab and Its Phase 3 Trial: Yung Chyung, MDThe chief medical officer of Scholar Rock discussed the upcoming phase 3 trial for apitegromab in SMA and whether a successful trial would warrant FDA submission.
Latest:
Del-Zota Produced Statistically Significant Increases in Exon-Skipping and Dystrophin Levels in EXPLORE44, a Phase 1/2 Study in Individuals With DMD44MAravindhan Veerapandiyan, MD, discusses how del-zota (delpacibart zotadirsen), an exon 44 skipping agent using antibody-conjugated phosphorodiamidate morpholino oligomer (PMO) technology, demonstrated favorable safety, significant dystrophin production (25% of normal), and unprecedented reduction of creatine kinase levels to near-normal in patients with Duchenne muscular dystrophy (DMD) during phase 1/2 clinical trials.
